391 related articles for article (PubMed ID: 33311949)
21. [Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study].
Zheng RH; Ding CF
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):98-101. PubMed ID: 18683746
[TBL] [Abstract][Full Text] [Related]
22. Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus.
Cervo A; Milic J; Mazzola G; Schepis F; Petta S; Krahn T; Lebouche B; Deschenes M; Cascio A; Guaraldi G; Sebastiani G
Clin Infect Dis; 2020 Dec; 71(10):e694-e701. PubMed ID: 32280969
[TBL] [Abstract][Full Text] [Related]
23. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS.
Petta S; Ciresi A; Bianco J; Geraci V; Boemi R; Galvano L; Magliozzo F; Merlino G; Craxì A; Giordano C
PLoS One; 2017; 12(11):e0186136. PubMed ID: 29161258
[TBL] [Abstract][Full Text] [Related]
24. High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance.
Cai J; Wu CH; Zhang Y; Wang YY; Xu WD; Lin TC; Li SX; Wang LH; Zheng J; Sun Y; Liu W; Tao T
Int J Obes (Lond); 2017 Sep; 41(9):1341-1347. PubMed ID: 28487551
[TBL] [Abstract][Full Text] [Related]
25. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome.
Targher G; Solagna E; Tosi F; Castello R; Spiazzi G; Zoppini G; Muggeo M; Day CP; Moghetti P
J Endocrinol Invest; 2009 Sep; 32(8):695-700. PubMed ID: 19542757
[TBL] [Abstract][Full Text] [Related]
26. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Kelley CE; Brown AJ; Diehl AM; Setji TL
World J Gastroenterol; 2014 Oct; 20(39):14172-84. PubMed ID: 25339805
[TBL] [Abstract][Full Text] [Related]
27. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome.
Doycheva I; Ehrmann DA
Fertil Steril; 2022 May; 117(5):897-911. PubMed ID: 35512974
[TBL] [Abstract][Full Text] [Related]
28. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
Brzozowska MM; Ostapowicz G; Weltman MD
J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
[TBL] [Abstract][Full Text] [Related]
29. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
[TBL] [Abstract][Full Text] [Related]
30. Non-alcoholic fatty liver disease in polycystic ovarian syndrome in Indian women.
Siwatch S; Singh V; Dhaliwal LK; Kumari S; Singh K
J Obstet Gynaecol; 2022 Jul; 42(5):957-961. PubMed ID: 34689689
[TBL] [Abstract][Full Text] [Related]
31. MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.
Macut D; Božić-Antić I; Bjekić-Macut J; Tziomalos K
Eur J Endocrinol; 2017 Sep; 177(3):R145-R158. PubMed ID: 28694246
[TBL] [Abstract][Full Text] [Related]
32. Hepatic steatosis in women with polycystic ovary syndrome.
Hong X; Guo Z; Yu Q
BMC Endocr Disord; 2023 Sep; 23(1):207. PubMed ID: 37752440
[TBL] [Abstract][Full Text] [Related]
33. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?
Targher G; Rossini M; Lonardo A
Endocrine; 2016 Feb; 51(2):211-21. PubMed ID: 26024975
[TBL] [Abstract][Full Text] [Related]
34. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
35. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.
Macut D; Bjekić-Macut J; Livadas S; Stanojlović O; Hrnčić D; Rašić-Marković A; Milutinović DV; Mladenović V; Andrić Z
Curr Pharm Des; 2018; 24(38):4593-4597. PubMed ID: 30652641
[TBL] [Abstract][Full Text] [Related]
36. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.
Jones H; Sprung VS; Pugh CJ; Daousi C; Irwin A; Aziz N; Adams VL; Thomas EL; Bell JD; Kemp GJ; Cuthbertson DJ
J Clin Endocrinol Metab; 2012 Oct; 97(10):3709-16. PubMed ID: 22837189
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
[TBL] [Abstract][Full Text] [Related]
38. Polycystic Ovary Syndrome and Metabolic Syndrome: Clinical and Laboratory Findings and Non-Alcoholic Fatty Liver Disease Assessed by Elastography.
Lavor CBH; Viana Júnior AB; Medeiros FDC
Rev Bras Ginecol Obstet; 2022 Mar; 44(3):287-294. PubMed ID: 35576937
[TBL] [Abstract][Full Text] [Related]
39. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
40. The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome.
Sarkar M; Terrault N; Duwaerts CC; Tien P; Cedars MI; Huddleston H
Curr Opin Gynecol Obstet; 2018 Feb; 1(1):24-33. PubMed ID: 30112518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
